BACKGROUND: Clinical, neurophysiological, and pathological evidence suggest an association between Parkinson's disease (PD) and peripheral neuropathy (PNP), with a possible causative role of levodopa metabolic products, such as homocysteine and methylmalonic acid. METHODS: We conducted a systematic review of studies reporting cases of PNP in l-dopa-treated PD patients indexed in PubMed between January 1990 and March 2018. RESULTS: We identified 38 articles reporting cases of PNP in PD patients treated with oral l-dopa or with l-dopa/carbidopa intestinal gel infusion (LCIG). Prevalence of PNP was 30.2% in the former group and 42.1% in the latter. Oral l-dopa was mostly associated with slowly progressive PNP, whereas LCIG showed an acute or subacute onset in 35.7% of cases. In both groups, there was an association between PNP and higher l-dopa doses, as well as with the following biochemical alterations: increased homocysteine; reduced vitamin B12; increased methylmalonic acid; and reduced vitamin B6. A skin biopsy was performed in 181 patients, showing signs of small fibers neuropathy in 169 (93.4%). Positive, yet preliminary, results were observed in patients receiving periodic vitamin supplementation. CONCLUSIONS: Over one third of PD patients in treatment with l-dopa may develop PNP, with a significantly higher prevalence of acute and subacute forms in those receiving LCIG. Pathogenic mechanisms remain unclear, but possibly related to a complex interplay between peripheral neurodegenerative processes and l-dopa neurotoxic metabolites. Prospective, randomized, clinical trials are required to identify factors associated with the onset and progression of PD-associated PNP and clarify the protective role of B-group vitamin supplementation.
BACKGROUND: Clinical, neurophysiological, and pathological evidence suggest an association between Parkinson's disease (PD) and peripheral neuropathy (PNP), with a possible causative role of levodopa metabolic products, such as homocysteine and methylmalonic acid. METHODS: We conducted a systematic review of studies reporting cases of PNP in l-dopa-treated PD patients indexed in PubMed between January 1990 and March 2018. RESULTS: We identified 38 articles reporting cases of PNP in PD patients treated with oral l-dopa or with l-dopa/carbidopa intestinal gel infusion (LCIG). Prevalence of PNP was 30.2% in the former group and 42.1% in the latter. Oral l-dopa was mostly associated with slowly progressive PNP, whereas LCIG showed an acute or subacute onset in 35.7% of cases. In both groups, there was an association between PNP and higher l-dopa doses, as well as with the following biochemical alterations: increased homocysteine; reduced vitamin B12; increased methylmalonic acid; and reduced vitamin B6. A skin biopsy was performed in 181 patients, showing signs of small fibers neuropathy in 169 (93.4%). Positive, yet preliminary, results were observed in patients receiving periodic vitamin supplementation. CONCLUSIONS: Over one third of PD patients in treatment with l-dopa may develop PNP, with a significantly higher prevalence of acute and subacute forms in those receiving LCIG. Pathogenic mechanisms remain unclear, but possibly related to a complex interplay between peripheral neurodegenerative processes and l-dopa neurotoxic metabolites. Prospective, randomized, clinical trials are required to identify factors associated with the onset and progression of PD-associated PNP and clarify the protective role of B-group vitamin supplementation.
Entities:
Keywords:
LCIG; Parkinson's disease; levodopa; neuropathy; small fibers
Authors: Wenzhen Duan; Bruce Ladenheim; Roy G Cutler; Inna I Kruman; Jean Lud Cadet; Mark P Mattson Journal: J Neurochem Date: 2002-01 Impact factor: 5.372
Authors: Inna I Kruman; T S Kumaravel; Althaf Lohani; Ward A Pedersen; Roy G Cutler; Yuri Kruman; Norman Haughey; Jaewon Lee; Michele Evans; Mark P Mattson Journal: J Neurosci Date: 2002-03-01 Impact factor: 6.167
Authors: Peter Valkovic; Ján Benetin; Pavol Blazícek; L'udmila Valkovicová; Karin Gmitterová; Peter Kukumberg Journal: Parkinsonism Relat Disord Date: 2005-04-20 Impact factor: 4.891
Authors: David S Saperstein; Gil I Wolfe; Gary S Gronseth; Sharon P Nations; Laura L Herbelin; Wilson W Bryan; Richard J Barohn Journal: Arch Neurol Date: 2003-09
Authors: Vili Viljaharju; Tuomas Mertsalmi; K Amande M Pauls; Maija Koivu; Johanna Eerola-Rautio; Marianne Udd; Eero Pekkonen Journal: Mov Disord Clin Pract Date: 2021-11-04
Authors: Arturo Cuomo; Anna Crispo; Andrea Truini; Silvia Natoli; Orazio Zanetti; Paolo Barone; Marco Cascella Journal: J Pain Res Date: 2019-07-22 Impact factor: 3.133